Pfizer has announced that it is set to make an approximately €300 million capital investment in its Irish operations to support the further development of existing manufacturing sites in Grange Castle, Newbridge and Ringaskiddy.
The investment will provide additional manufacturing and laboratory capacity creating approximately 300 roles, with additional anticipated construction roles in Ringaskiddy, Cork. The investment and additional roles will be completed over the next 2 to 3 years.
The company will use the investment to upgrade and enhance existing facilities, expand manufacturing and laboratory capacity and add new technologies to ensure Pfizer is ready to support the next wave of medical innovations.
Part of the investment includes the initial stage of a project to construct a development facility on the existing Ringaskiddy site to manufacture pharmaceutical compounds for Pfizer’s clinical trials globally.
This is a very important development as it expands Pfizer’s role in Ireland from the manufacture of already approved medicines into supporting the earlier phases of new medicine development.
The Irish sites manufacture leading medicines and vaccines in the areas of arthritis, inflammation, cancer, anti-infectives, haemophilia, pain and stroke. The roles being recruited for comprise a broad range of highly skilled roles including; analysts, technicians, engineers, scientists, technologists, quality specialists, data analysts and chemists.
This announcement comes hard on the heels of Pfizer receiving clearance from the US Federal Trade Commission for the proposed combination of Mylan and Pfizer’s Upjohn Business.
Read the original article